期刊文献+

溴隐亭促进大鼠泌乳素瘤MMQ细胞分泌外泌体以及对细胞耐药性的影响 被引量:2

Bromocriptine promotes secretion of exosomes and drug resistance of rat prolactinoma MMQ cells in vitro
原文传递
导出
摘要 目的:探讨溴隐亭在促进大鼠泌乳素瘤MMQ细胞分泌外泌体,及其外泌体在MMQ细胞耐药中的作用。方法:采用CCK-8法检测不同浓度的溴隐亭对MMQ细胞增殖的影响,并计算半数抑制浓度(half maximal inhibitory concentration,IC50)值。MMQ细胞在溴隐亭中暴露48 h后,采用差速离心法分离收集外泌体;在透射电子显微镜下观察外泌体形态和大小,纳米颗粒跟踪分析仪检测外泌体粒径,蛋白质印迹法检测外泌体表面标志物CD63的表达情况。用PKH67标记外泌体,在激光共聚焦显微镜下观察外泌体被MMQ细胞摄取的情况;采用CCK-8法检测外泌体被摄取后,MMQ细胞对溴隐亭敏感性的改变。实时荧光定量PCR法检测外泌体处理后对MMQ细胞中PR结构域锌指蛋白2(PR domain zincnger protein 2,PRDM2)mRNA表达的影响;蛋白质印迹法检测外泌体处理后对MMQ细胞中PRDM2、多巴胺2受体(dopamine 2 receptor,D2R)和细胞外信号调节激酶1/2(extracellular signal-regulated kinase 1/2,ERK1/2)以及磷酸化ERK1/2(phospho-ERK1/2,p-ERK1/2)表达水平的影响。结果:溴隐亭对MMQ细胞的IC50值为(52.91±1.48)μmol/L;与未用溴隐亭处理的MMQ细胞所分泌的外泌体相比,溴隐亭处理MMQ细胞所分泌的外泌体颗粒数和蛋白质含量均显著增加(P值均<0.01),但粒径没有变化。与MMQ细胞相比,仅有外泌体上有CD63的表达。溴隐亭处理MMQ细胞所分泌的外泌体可以被MMQ细胞所摄取;MMQ细胞摄取外泌体后,溴隐亭对MMQ细胞的IC50值为(73.74±1.17)μmol/L,较未摄取外泌体的MMQ细胞明显提高(P<0.01);MMQ细胞摄取外泌体后,MMQ细胞中PRDM2 mRNA和蛋白的表达水平明显下调(P值均<0.05),D2R蛋白的表达水平也明显降低(P<0.05),p-ERK1/2蛋白的表达水平升高(P<0.05)。结论:溴隐亭可促进大鼠泌乳素瘤MMQ细胞分泌外泌体,并且在溴隐亭治疗时所产生的外泌体可通过在肿瘤细胞间传递信息,从而使MMQ细胞获得耐药性。 Objective:To investigate the effect of bromocriptine on the secretion of exosomes and the role of exosomes in drug resistance of rat prolactinoma MMQ cells.Methods:The effect of different concentrations of bromocriptine on the proliferation of MMQ cells was detected by CCK-8 assay,and the half maximal inhibitory concentration(IC50)was calculated.MMQ cells were exposed to bromocriptine for 48 h,then the exosomes were isolated by differential centrifugation.The morphology of exosomes was observed by transmission electron microscopy,the particle size of exosomes was analyzed by nanoparticle tracking analysis(NTA),and the expression of exosomal marker CD63 was detected by Western blotting.MMQ cells uptaking PKH67-labeled exosomes were observed by laser confocal microscopy.Then the sensitivity of MMQ cells to bromocriptine was tested again by CCK-8 method.The expression level of PR domain zinc finger protein 2(PRDM2)mRNA in MMQ cells treated with exosomes was detected by real-time fluorescent quantitative PCR.The expression levels of PRDM2,dopamine 2 receptor(D2R),extracellular signal-regulated kinase 1/2(ERK1/2)and phospho-ERK1/2(p-ERK1/2)proteins in MMQ cells treated with exosomes were determined by Western blotting.Results:The IC50 of bromocriptine on MMQ cells was(52.91±1.48)μmol/L.Compared with the exosomes collected from MMQ cells not treated with bromocriptine,the particles and proteins in exosomes collected from MMQ cells treated with 50μmol/L bromocriptine were significantly increased(both P<0.01).The expression of CD63 was only observed in the exosomes.The exosomes collected from MMQ cells treated with bromocriptine were uptaken by MMQ cells.After the exosomes were absorbed by MMQ cells,the IC50 of bromocriptine[(73.74±1.17)μmol/L]was increased on MMQ cells(P<0.01).In exosome-treated MMQ cells,the expression levels of PRDM2 mRNA and protein(both P<0.05)and D2R protein(P<0.05)were down-regulated,while the expression level of p-ERK1/2 was higher than that in the control group(P<0.05).Conclusion:Bromocriptine can promote the secretion of exosomes in MMQ cells,and the exosomes may be involved in the transmission of information through intercellular communication of tumors,which can make MMQ cells to obtain drug resistance.
作者 黄华 王福超 谭松 牟家民 金彪 杨刚 HUANG Hua;WANG Fuchao;TAN Song;MOU Jiamin;JIN Biao;YANG Gang(Department of Neurosurgery,First Affiliated Hospital,Chongqing Medical University,Chongqing 400016,China)
出处 《肿瘤》 CAS CSCD 北大核心 2019年第7期515-524,共10页 Tumor
关键词 催乳素瘤 外泌体 溴隐亭 细胞增殖 抗药性 肿瘤 Prolactinoma Exosomes Bromocriptine Cell proliferation Drug resistance,neoplasm
  • 相关文献

参考文献2

二级参考文献20

  • 1Imran SA, Ur E, Clarke DB. Managing prolactin-secreting adenomas during pregnancy [ J]. Can Fam Physician, 2007, 53 (4) : 653 -658.
  • 2Huda MS, Athauda NB, Teh MM, et al. Factors determining the remission of microprolactinomas after dopamine agonist withdrawal [ J ]. Clin Endocrinol (Oxf), 2010, 72(4): 507-511.
  • 3Sinha S, Shama BS, Mahapatra AK. Microsurgical management of prolactinomas-Clinica and hormonal outcome in a series of 172 cases [J]. Neurol India, 2011,59(4) : 532 -536.
  • 4Massoud F, Serri O, Hardy J, et al. Transsphenoidal adenomectomy for microprolactinomas: 10 to 20 years of follow-up [J]. Surg Neurol, 1996, 45(4) : 341 -346.
  • 5Biswas M, Smith J, Jadon P, et al. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas [J]. Clin Endocrinol (Oxf), 2005, 63(1): 26- 31.
  • 6dos Santos Nunes V, El Dib R, Boquszewski CL, et al. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis [ J ]. Pituitary, 2011, 14(3): 259-265.
  • 7Colao A, Pivonello R, Di Somma C, et al. Medical therapy of pituitary adenomas: effects on tumor shrinkage [ J]. Rev Endocr Metab Disord, 2009, 10(2): 111-123.
  • 8Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor [J]. Endocr Rev, 2001, 22(6) : 724 -763.
  • 9Oh MC, Aghi MK. Dopamine agonist-resistant prolactinomas [ J]. J Neurosurg, 2011, 114(5): 1369-1379.
  • 10Alberiche Ruano M, Boronat Cortes M, Ojeda Pino A, et al. Acquired resistance to cabergoline: progression from initially responsive micro to macroprolactinoma [ J ]. Pituitary, 2010, 13 (4) : 380 - 382.

共引文献20

同被引文献17

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部